secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001326110-25-000143
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio receives EMA positive opinion for ANKTIVA+BCG in NMIBC CIS in Europe
--------------------------------------------------------------------------------

- EMA recommends conditional marketing authorization for ANKTIVA+BCG to treat BCG-unresponsive NMIBC with CIS.
- Decision based on single-arm trial: 71% complete response rate, median duration ~27 months (up to 54+ months).
- Over 150,000 Europeans diagnosed with NMIBC annually; no authorized treatment currently for BCG-unresponsive cases.
- Opinion forwarded to European Commission for final EU-wide approval; company to submit long-term follow-up data.
- Six BCG strains available in Europe; ImmunityBio developing recombinant BCG to address U.S. shortages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/0001326110-25-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000143/ibrx-20251212.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer